Top Warren Buffett Companies To Own In Right Now

One home-run investing opportunity has been slipping under Wall Street's radar for months. But it won't stay hidden much longer. Forward-thinking energy players such as General Electric and Ford have already plowed sizable amounts of research capital into this little-known stock, because they know it holds the key to the explosive profit power of the coming "no choice fuel revolution." Luckily, there's still time for you to get on board if you act quickly. All the details are inside an exclusive report from The Motley Fool. Click here for the full story!

For some newer avenues that natural gas might find itself headed down, look no further than railway and marine transportation. Already, there has been public buy-in from some of the biggest companies in the United States. Earlier this year, Warren Buffett's Berkshire Hathaway (NYSE: BRK-A  ) made it well known that its portfolio company, BNSF, would begin testing the use of liquified natural gas as a substitute for diesel fuel in its locomotives. This could have huge positive implications for the natural gas industry and equally negative effects on the diesel fuel sector.

Hot Cheap Stocks To Buy Right Now: Conmed Corp (CNMD)

CONMED Corporation (CONMED), incorporated on February 10, 1970, is a medical technology company/ The Company emphasizes on surgical devices and equipment for minimally invasive procedures and monitoring. The Company's products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. The Company operates in five segments: CONMED Endoscopic Technologies, CONMED Endosurgery, CONMED Electrosurgery, CONMED Linvatec and CONMED Patient Care.

Arthroscopy

The Company offers a range of devices and products for uses in arthroscopic surgery. The Company's arthroscopy products include powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, metal and bioabsorbable implants as well as related disposable products and fluid management systems. The Company also offers a line of video Endoscopy products suitable for uses in multi-specialty clinical environments beyond orthopedic arthroscopy, including laparoscopy, ear, nose and throat (ENT), gynecology and urology, as well as integrated operating room systems and equipment.

Powered Surgical Instruments

Electric, battery or pneumatic powered surgical instruments are used to perform orthopedic, arthroscopic and other surgical procedures where cutting, drilling or reaming of bone is required. Each power system consists of one or more handpieces and related accessories as well as disposable and limited reusable items (e.g., burs, saw blades, drills and reamers). Powered instruments are categorized as either small bone, large bone or specialty powered instruments. Specialty powered instruments are utilized in procedures such as spinal surgery, neurosurgery, ENT, oral/maxillofacial surgery, and cardiothoracic surgery.

The Company's line of powered instruments is sold principally under the Hall Surgical brand name, for use in large and small bone orthopedic, arthroscopic, oral/maxillofaci! al, podiatric, plastic, ENT, neurological, spinal and cardiothoracic surgeries. Large bone, neurosurgical, spinal and cardiothoracic powered instruments are sold primarily to hospitals while small bone arthroscopic, otolaryngological and oral/maxillofacial powered instruments are sold to hospitals, outpatient facilities and physicians offices.

The Company's powered instruments product line includes the MPower battery system. This orthopedic power system is specifically designed to meet the requirements of orthopedic applications. The MPower battery system allows a facility to purchase a single power system to perform total joint arthroplasty, trauma, arthroscopy, and small bone procedures. The system also provides a multitude of battery technologies to meet the varying needs of hospitals worldwide.

Electrosurgery

The use of electrosurgical units and associated surgical tools is commonplace in the hospital surgical suite, surgery centers, clinics and physician offices. Electrosurgery is routinely used to cut and coagulate tissue and small vessels in open and laparoscopic procedures using energy produced through radio frequency (RF) technology. Electrosurgery can be used in almost all surgical procedures including specialties, such as general, gynecology, orthopedics, cardiology, thoracics, urology, neurology, and dermatology. The Company�� portfolio consist of energy-based products is the Argon Beam Coagulation (ABC) technology. ABC technology combines the use of argon gas and electrosurgical energy to allow the surgeon to produce a surface coagulation which results in less tissue damage.

Patient Care

The Company's patient care product line includes a line of vital signs and cardiac monitoring products, including pulse oximetry equipment and sensors, electrocardiogram (ECG) electrodes and cables, cardiac defibrillation and pacing pads and blood pressure cuffs. The Company also offers a line of suction instruments and tubing for use in the! operatin! g room, as well as a line of intravenous (IV) products for use in the critical care areas of the hospital.

Endosurgery

Endosurgery (also referred to as minimally invasive surgery or laparoscopic surgery) is surgery performed without a incision. The Company's Endosurgical products include the Reflex and PermaClip clip appliers for vessel and duct ligation, Universal S/I (suction/irrigation) and Universal Plus laparoscopic instruments and specialized suction/irrigation electrosurgical instrument systems for use in laparoscopic surgery. The Company also offers cutting and dilating trocars, suction/irrigation accessories, laparoscopic scissors, dissectors and graspers, active electrodes, insufflation needles and linear cutters and staplers for use in laparoscopic surgery. The Company's disposable skin staplers are used to close large skin incisions with surgical staples, thus eliminating the time consuming suturing process. CONMED Endosurgery also offers a uterine manipulator called VCARE for use in increasing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures.

Endoscopic Technologies

The Company offers a line of minimally invasive diagnostic and therapeutic products used in conjunction with procedures, which requires flexible endoscopy. The Company's principal customers include gastrointestinal (GI) endoscopists, pulmonologists, and nurses who perform both diagnostic and therapeutic endoscopic procedures in hospitals and outpatient clinics.

The Company's primary focus is to identify, develop, acquire, manufacture and market differentiated medical devices, which improve outcomes in the diagnosis and treatment of gastrointestinal and pulmonary disorders. The Company's diagnostic and therapeutic product offerings for GI and pulmonology include mucosal management devices, forceps, scope management accessories, bronchoscopy devices, dilatation, stricture management devices, hemostasis, biliary devices, and ! polypecto! my.

The Company competes with Smith & Nephew, plc, Arthrex, Inc., Stryker Corporation, ArthroCare Corporation, Johnson & Johnson: DePuy Mitek, Inc., Biomet, Inc., Medtronic, Inc. Midas Rex and Xomed, Synvasive Technology, Inc., Synthes, Inc., MicroAire Surgical Instruments, LLC, Zimmer Holdings, Inc., Covidien Ltd.; Valleylab, Medline Industries, Inc., ERBE Elektromedizin GmbH, Megadyne, Kendall, 3M Company, Ethicon Endo-Surgery, Inc, U.S.Surgical, Boston Scientific Corporation, Wilson-Cook Medical, Inc, Olympus America, Inc. and STERIS Corporation.

Advisors' Opinion:

• [By Seth Jayson]

  Margins matter. The more CONMED (Nasdaq: CNMD  ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong CONMED's competitive position could be.

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on CONMED (Nasdaq: CNMD  ) , whose recent revenue and earnings are plotted below.

• [By James Brumley]

  Shares of MDT stock have fallen 6% since their early January peak, but have been in an uptrend since late 2011 … one of the few stocks in the medical device world that has been rock-solid in a rocky environment.

  Medical Devices: ConMed Corp. (CNMD)

  With a market cap of only $1.2 billion, ConMed Corp. (CNMD) isn’t exactly a household name. That doesn’t mean CNMD stock can’t be a potent addiction to a portfolio, though.

Top Warren Buffett Companies To Own In Right Now: RDA Microelectronics Inc.(RDA)

RDA Microelectronics, Inc., a fabless semiconductor company, designs, develops, and markets radio-frequency and mixed-signal semiconductors for cellular, broadcast, and connectivity applications. Its products include power amplifiers, transceivers and front-end modules, FM radio receivers and transmitters, set-top box tuners, analog mobile television receivers, walkie-talkie transceivers, LNB satellite downconverters, and Bluetooth system-on-chips for mobile handsets. The company?s products also comprise GSM/EDGE power amplifier modules, GSM transceivers, TD-SCDMA transceivers, SCDMA transceivers, 3G switch modules, GSM power amplifier and switch modules, PHS transceivers, TD-SCDMA/GSM dual-mode transceivers, and radio frequency switches; DVB-T tuners, DVB-S and DVB-S2 satellite tuners, analog mobile television receiver system-on-chips, and FM radio receivers with radio data system; and Bluetooth + FM system-on-chips for mobile handsets and walkie-talkie transceivers for professional applications. Its products are incorporated into mobile handsets, set-top boxes, MP3 players, and other wireless and consumer electronic devices. RDA Microelectronics sells its products through distributors in the People?s Republic of China, southeast Asia, India, the Middle East, Africa, the Russian Federation, and Latin America. The company was founded in 2004 and is headquartered in Shanghai, the People?s Republic of China.

Advisors' Opinion:

• [By Lauren Pollock]

  RDA Microelectronics Inc.(RDA) has received a takeover proposal from Shanghai Pudong Science & Technology Investment Co. valuing the Chinese semiconductor company at $745 million. PDSTI, a state-owned investment company, offered to buy RDA for $15.50 an American depositary share, a 12% premium to RDA’s closing price Thursday. RDA shares were halted premarket ahead of the news.

• [By Luke Jacobi]

  RDA Microelectronics (NASDAQ: RDA) shot up 11.96 percent to $15.54 after the company received a non-binding acquisition proposal.

  Finish Line (NASDAQ: FINL) got a boost, shooting up 9.02 percent to $24.41 after the company reported a 6.1 percent rise in its fiscal second-quarter earnings.

• [By Jake L'Ecuyer]

  RDA Microelectronics (NASDAQ: RDA) was also up, gaining 11.12 percent to $17.28 after the company announced the receipt of $18.00/ADS acquisition proposal from Tsinghua Unigroup.

Top Warren Buffett Companies To Own In Right Now: Bounty Oil and Gas NL (BUY)

Bounty Oil & Gas NL (Bounty) is an Australia-based company engaged in the exploration, development, production and marketing of oil and gas (petroleum). The Company operates in two segments: Core Petroleum Segment and Secondary Segment. The Core Petroleum Segment is involved in oil and gas exploration, development and production. The Secondary Segment is involved in the Investment in listed securities. During the fiscal year ended June 30, 2012 (fiscal 2012), the Company produced light sweet crude oil from the Murta Zone in the Utopia Field , southwest Queensland and continued to sell the oil to the Eromanga Refinery 50 kilometers north of the field; produced oil from several oil fields and leases operated by Santos Limited in ATP 259P, Naccowlah Block, southwest Queensland, and achieved revenue from sale of listed investments. The Company also operates Nyuni Joint Venture which is offshore Tanzania, East Africa. Advisors' Opinion:

• [By wax]

  Positive (buy) investment interest means that the current key performance indicators (KPIs) favor investment consideration at this time.

  The recent close of $10.01 is approximately 13% below the fair value buy target for the stock and approximately 58% below the fair value close target for the stock. The recent close is also 5% above analysts��twelve-month $9.50 median price target for the stock.

Top Warren Buffett Companies To Own In Right Now: CombiMatrix Corporation(CBMX)

CombiMatrix Corporation, a molecular diagnostics company, operates primarily in the fields of genetic analysis and molecular diagnostics in the United States. The company, through its wholly owned subsidiary, CombiMatrix Diagnostics, operates a diagnostics reference laboratory that provides DNA-based clinical diagnostic testing services to physicians, hospitals, and other laboratories in two primary areas, including prenatal and postnatal developmental disorders, and oncology. It offers a suite of developmental disorder array tests on the prenatal and postnatal application of array-comparative genomic hybridization in diagnosing genomic syndromes associated with developmental delays, autism spectrum disorders, dysmorphic features, and/or birth defects. The company also provides DNAarray?Heme Profile test to address various common hematological malignancies, including chronic lymphocytic leukemia; DNAarray?HER2 PRO test for breast cancer; and DNAarray?Tumor Profile test for the analysis of solid tumors, including breast, colon, lung, prostate, and brain tumors. In addition, it focuses on developing a series of drug compounds to address various oncology-related diseases. CombiMatrix Corporation was founded in 1995 and is based in Irvine, California.

Advisors' Opinion:

• [By Bryan Murphy]

  Looking for a couple of long (bullish) trading ideas on a day when the market is dragging pretty much everything lower? There are two names that fit the bill...CombiMatrix Corp. (NASDAQ:CBMX) and Banro Corporation (NYSEMKT:BAA). CBMX is an "almost" small cap stock that deserves a place on your watchlist while we wait for it to do one more thing. Meanwhile, BAA is something worth going ahead and taking a swing on now, not despite the market's tumble, but because of it.

• [By Wallace Witkowski]

  Also, shares of Combimatrix Corp. (CBMX) rose 7.5% to $2.73 in moderate volume late Friday following a Securities and Exchange Commission filing showing Longwood Capital Partners acquired a 5.1% stake in the microcap molecular diagnostics company.

Top Warren Buffett Companies To Own In Right Now: Navidea Biopharmaceuticals Inc (NAVB)

Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, incorporated in 1983, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company�� radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection), a radiopharmaceutical agent for lymph node mapping; AZD4694, an imaging agent, and RIGScan, a tumor antigen-specific targeting agent. In January 2012, the Company executed an option agreement with Alseres Pharmaceuticals, Inc. (Alseres) to license [123I]-E-IACFT Injection, also called Altropane, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson�� disease, movement disorders and dementia. In August 2011, the Company sold its gamma detection device line of business (the GDS Business) to Devicor Medical Products, Inc.

Lymphoseek

Navidea�� pipeline includes clinical-stage radiopharmaceutical agents used to identify the presence and status of disease. Lymphoseek (Kit for the Preparation of Technetium Tc99m for Injection) is a lymph node targeting agent intended for use in intraoperative lymphatic mapping (ILM) procedures and lymphoscintigraphy employed in the overall diagnostic assessment of certain solid tumor cancers. The lymph system is a component of the body�� immune system. The key components of the lymph system are lymph nodes-small anatomic structures that contain disease-fighting lymphocytes, filter lymph of bacteria and cancer cells, and signal infection in response to heightened levels of pathogens. In Navidea�� Phase III clinical studies of Lymphoseek, it detected over 99% of positive nodes identified by vital blue dye (VBD). As of December 31, 2011, Navidea, in co-operation with UC, San Diego affiliate (UCSD), completed or initiated five Phase I clinical trials, one multi-center Phase II trial and three multi-center Phase II trials inv! olving Lymphoseek. Two Phase III studies were completed in subjects with breast cancer and melanoma. During the year ended December 31, 2011, data from NEO3-09 were released, which indicated that all primary and secondary endpoints for the study were met. As of December 31, 2011, third Phase III clinical trial for Lymphoseek in subjects with head and neck squamous cell carcinoma (NEO3-06) was in progress.

AZD4694

AZD4694 is a Fluorine-18 labeled precision radiopharmaceutical candidate for use in the imaging and evaluation of patients with signs or symptoms of cognitive impairment such as Alzheimer's disease (AD). It binds to beta-amyloid deposits in the brain that can then be imaged in positron emission tomography (PET) scans. Amyloid plaque pathology is a required feature of AD and the presence of amyloid pathology is a supportive feature for diagnosis of probable AD. Patients who are negative for amyloid pathology do not have AD. AZD4694 has been studied in several clinical trials. Clinical studies through Phase IIa have included more than 80 patients to date, both suspected AD patients and healthy volunteers. No significant adverse events have been observed. Results suggest that AZD4694 has the ability to image patients quickly and safely with high sensitivity.

RadioImmunoGuided Surgery

As of December 31, 2011, RIGScan had been studied in a number of clinical trials, including Phase III studies. Navidea has conducted two Phase III studies, NEO2-13 and NEO2-14, of RIGScan in patients with primary and metastatic colorectal cancer, respectively. Both studies were multi-institutional involving cancer treatment institutions in the United States, Israel, and the European Union.

The Company competes with Pharmalucence, Eli Lilly, Bayer Schering, General Electric and GE Healthcare.

Advisors' Opinion:

• [By Sean Williams]

  Diagnostics can also play an important role in early and late-stage breast cancer diagnoses. Navidea Biopharmaceuticals (NYSEMKT: NAVB  ) had Lymphoseek, its external lymph-node imaging and intra-operative lymphatic mapping diagnostic device, approved by the Food and Drug Administration earlier this year to help doctors stage cancer. Discovering whether breast cancer has invaded adjacent lymph nodes has never been easier or safer thanks to Lymphoseek, and it can dramatically aid physicians in determining the best course of action for breast cancer patients.

• [By Lauren Pollock]

  Among the companies with shares expected to actively trade in Tuesday’s session are Toll Brothers Inc.(TOL) and Navidea Biopharmaceuticals Inc.(NAVB)

• [By Keith Speights]

  3. Navidea Biopharmaceuticals (NYSEMKT: NAVB  )
  Some investors were likely befuddled by Navidea's stock action earlier this year. The company received FDA approval in March for Lymphoseek, its radiopharmaceutical agent used for imaging lymph nodes in patients with breast cancer or melanoma. That was great news, but shares dropped quickly and still haven't returned to previous levels.

Top Warren Buffett Companies To Own In Right Now: Acuity Brands Inc (AYI)

Acuity Brands, Inc. (Acuity Brands), incorporated on September 20, 2007, is the parent company of Acuity Brands Lighting, Inc. (ABL), and other subsidiaries. Acuity Brands is a provider of lighting solutions for commercial, institutional, industrial, infrastructure, and residential applications throughout North America and select international markets. The Company's lighting solutions include devices, such as luminaires, lighting controls, power supplies, prismatic skylights, light-emitting diode (LED) lamps, and integrated lighting systems for indoor and outdoor applications utilizing a combination of light sources, including daylight, and other devices controlled by software that monitors and manages light levels while optimizing energy consumption (collectively referred to herein as lighting solutions). Effective March 14, 2013, the Company acquired eldoLED Europe BV.

The Company manufactures lighting devices primarily in North America, Europe and Asia. The Company's lighting solutions are marketed under numerous brand names, including Lithonia Lighting, Holophane, Peerless, Mark Architectural Lighting, Hydrel, American Electric Lighting, Gotham, Carandini, RELOC, Antique Street Lamps, Tersen, Winona Lighting, Synergy Lighting Controls, Sensor Switch, Lighting Control & Design, Dark to Light, ROAM, Sunoptics, acculamp, Pathway Connectivity, and Healthcare Lighting. As of August 31, 2012, the Company manufactures products in 18 facilities in North America and two facilities in Europe.

Principal customers include electrical distributors, retail home improvement centers, electric utilities, municipalities, lighting showrooms, and energy service companies located in North America and select international markets serving new construction, renovation, and facility maintenance applications. In North America, the Company's lighting solutions are sold primarily by independent sales agents, electrical wholesalers, and factory sales representatives who cover specific geographic areas! and market channels. Products are delivered directly or through a network of distribution centers, regional warehouses, and commercial warehouses using both common carriers and a company-owned truck fleet. During the fiscal year ended August 31, 2012 (fiscal 2012), North American sales accounted for approximately 98% of net sales. The Company has one operating segment serving the North American lighting market and select international markets.

The Company provides a range of lighting solutions, as well as services used in the applications, such as lighting solutions and services. Lighting solutions and services includes commercial and institutional, industrial, infrastructure, residential and services. Commercial and Institutional includes stores, hotels, offices, schools, and hospitals, as well as other government and public buildings. Lighting solutions that serve these applications include recessed, surface, and suspended lighting products, recessed down lighting, track lighting, day lighting, and lighting controls (occupancy sensors, photocontrols, relay panels, architectural dimming panels, and integrated lighting controls systems), as well as special-use lighting products. The outdoor areas associated with these applications are addressed by a range of outdoor lighting products, such as area and flood lighting, decorative site lighting, and landscape lighting. Industrial includes primarily warehouses and manufacturing facilities, which utilize a range of general purpose, day lighting, and special-use lighting solutions. Infrastructure includes highways, tunnels, airports, railway yards, and ports. Products that serve these applications include street, area, high-mast, off-set roadway, sign lighting, poles, and integrated controls systems. Residential includes a combination of decorative, utilitarian, and down lighting products. Services include monitoring and controlling of lighting systems through network technologies.

The Company competes with Cooper Industries plc, Hu! bbell Inc! orporated, Koninklijke Philips Electronics N.V., OSRAM AG, Schneider Electric and General Electric Company.

Advisors' Opinion:

• [By Mike Deane]

  Acuity Brands announced its second quarter earnings just as the opening bell rang on Wednesday, with the company posting slightly higher revenue and earnings than last year’s Q2.�

  AYI’s Earnings in Brief

  AYI reported fourth quarter revenues of $546.2 million, an increase of 12% million from last year’s Q2 revenues of $486.7 million. Net income for the quarter came in at $77.2 million, up from $50.8 million reported for last year’s Q2. The company�� diluted EPS for Q2 was 75 cents, an increase from last year’s 57 cent EPS. AYI missed analysts’ estimates of 83 cents EPS on revenues of $553.95 million. Looking ahead, AYI has a positive outlook on the lighting industry, and sees growth and strong demand.

  CEO Commentary

  AYI’s chairman, president and CEO, Vernon J. Nagel, had the following comments: “We were very pleased with our fiscal 2014 second quarter results as we continued to execute our strategies to extend our leadership position in North America. While we believe inclement winter weather in certain parts of the U.S. dampened customer orders during the quarter and somewhat impacted our operations, the year-over-year increase in net sales reflects continued favorable trends in order rates as well as the continued adoption of LED lighting solutions, which again more than doubled over the prior year. Sales of LED-based luminaires now represent 30 percent of our�net sales. We believe our second quarter results reflect our ability to provide customers truly differentiated value from our industry-leading portfolio of innovative lighting and control solutions along with superior service.”

  AYI’s Dividend

  Acuity is paying its next dividend on May 1, and its stock goes ex-dividend on April 15. The company pays a quarterly dividend of 13 cents, which has not been touched since 2007.

  Stock Performance

  AYI stock was up slightly on Wednesday morning. YTD, the c

• [By Rich Bieglmeier]

  [Related -Acuity Brands, Inc. (AYI) Q2 Earnings Preview: Red Lighting Earnings And Performance As Of Late]

  Liu Chun-ting, director general for Electronics and Optoelectronics Research Laboratories (EORL) under Taiwan government-sponsored Industrial Technology Research Institute (ITRI) projects a little stronger number, "Global LED lighting market value is estimated at US$30.5 billion for 2014 and will increase to US$51.6 billion in 2018."

• [By Garrett Cook]

  Acuity Brands (NYSE: AYI) shares tumbled 14.44 percent to $118.25 after the company reported weaker-than-expected third-quarter results.

  WGP) was down, falling 2.81 percent to $60.94 as the company priced 5 million units at $60.19 per unit.

• [By Steve Symington]

  That said, both UDC and its licensed customers have long remained hard at work continuously improving both the efficiency and utility of OLED lighting solutions, with those lighting-centric customers most notably including electronics giants like Philips (NYSE: PHG  ) �and their respective Lumiblade series, design extraordinaire�Acuity Brands (NYSE: AYI  ) , and LG Chem, which reportedly plans to begin mass-producing the flexible OLED lighting panels shown in the video below, as soon as September: